Prognostic value of immunoexpression of the chemoresistance-related proteins in ependymomas: An analysis of 76 cases

Journal of Neuro-Oncology

Volumn 45, Issue 3, 1999, Pages 219-227

  Korshunov, Andrey ^a   Sycheva, Regina ^a   Timirgaz, Valery ^a   Golanov, Andrey ^a  

^a BURDENKO NEUROSURGICAL INSTITUTE   (Russian Federation)

Author keywords

Ependymoma; Glutathione S transferase pi; Metallothioneins; P glycoprotein; Progression

Indexed keywords

ANTIBODY; CELL PROTEIN; CISPLATIN; ETOPOSIDE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; METALLOTHIONEIN; VINCRISTINE;

ADULT; ARTICLE; CELL SURVIVAL; CHILD; EPENDYMOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE RISK; STATISTICAL MODEL; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR GROWTH;

ADOLESCENT; ADULT; BRAIN NEOPLASMS; CHILD; DRUG RESISTANCE, NEOPLASM; EPENDYMA; EPENDYMOMA; FEMALE; FOLLOW-UP STUDIES; GLUTATHIONE TRANSFERASE; HUMANS; MALE; METALLOTHIONEIN; NEOPLASM RECURRENCE, LOCAL; P-GLYCOPROTEIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0033503169     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006369829576     Document Type: Article

References (55)

1. Applegate GL, Marymont M: Intracranial ependymomas: a review. Cancer Invest 16: 588-593, 1998
2. Bouffet E, Perilongo G, Canete A, Massimino M: Intracranial ependymomas in children: a critical review of prognostic factors and a plea for cooperation. Med Pediatr Oncol 30: 319-329, 1998
3. Ernestus RI, Schröder R, Stützer H, Klug N: The clinical and prognostic relevance of grading in intracranial ependymomas. Br J Neurosurg 11: 421-428, 1997
4. Foreman NK, Love S, Thorne R: Intracranial ependymomas: analysis of prognostic factors in a population-based series. Pediatr Neurosurg 24: 119-125, 1996
5. Gerszten PC, Pollack IF, Martińez AJ, Lo KH, Janosky J, Albright AL: Intracranial ependymomas of childhood. Lack of correlation of histopathology and clinical outcome. Pathol Res Pract 192: 515-522, 1996
6. Kovalic JJ, Flaris N, Grigsby PW, Pirkowski M, Simpson JR, Roth KA: Intracranial ependymoma long term outcome, patterns of failure. J Neurooncol 15: 125-131, 1993
7. McLaughlin MP, Marcus RBJ, Buatti JM, McCollough WM, Mickle JP, Kedar A, Maria BL, Million RR: Ependymoma: results, prognostic factors and treatment recommendations. Int J Radiat Oncol Biol Phys 40: 845-850, 1998
8. Nazar GB, Hoffman HJ, Becker LE, Jenkin D, Humphreys RP, Hendrick EB: Infratentorial ependymomas in childhood: prognostic factors and treatment. J Neurosurg 72: 408-417, 1990
9. Perilongo G, Massimino M, Sotti G, Canete A: Analyses of prognostic factors in a retrospective review of 92 children with ependymoma: Italian Pediatric Neurooncology Group. Med Pediatr Oncol 29: 79-85, 1997
10. Pollack IF, Gerszten PC, Martinez AJ, Lo KH, Shultz B, Albright AL, Janosky J, Deutsch M: Intracranial ependymomas of childhood: long-term outcome and prognostic factors. Neurosurgery 37: 655-666, 1995
11. Robertson PL, Zeltzer PM, Boyett JM, Rorke LB, Allen JC, Geyer R, Stanley Ph, Li H, Albright L, McGuire-Gullen P, Finlay JL, Stevens KR, Milstein JM, Packer RJ, Wisoff J and the Children's Cancer Group: Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group. J Neurosurg 88: 695-703, 1998
12. Ross GW, Rubinstein LJ: Lack of histopathological correlation of malignant ependymomas with postoperative survival. J Neurosurg 70: 31-36, 1989
13. Schiffer D, Chio A, Cravioto H, Giordana MT, Migheli A, Soffietti R, Vigliani MC: Ependymoma: internal correlations among pathological signs: the anaplastic variant. Neurosurgery 29: 206-210, 1991
14. Schwartz TH, Kim S, Glick RS, Bagiella B, Balmaceda C, Fetell MR, Stein BM, Sisti MB, Bruce JN: Supratentorial ependymomas in adult patients. Neurosurgery 44: 721-731, 1999
15. Sutton LN, Goidwein J, Perilongo G: Prognostic factors in childhood ependymomas. Pediatr Neurosurg 16: 57-65, 1997
16. Evans AL, Anderson JR, Lefcowitz BL, Finlay JL: Adjuvant chemotherapy of childhood posterior fossa ependymoma: craniospinal irradiation with or without adjuvant CCNU, vincristin and prednisone: a Childrens Cancer Group study. Med Pediatr Oncol 27: 8-14, 1996
17. Fouladi M, Baruchel S, Chan H, Grant R, Malkin D, Weitzman S, Greenberg ML: Use of adjuvant ICE chemotherapy in the treatment of anaplastic ependymomas. Childs Nerv Syst 14: 590-595, 1998
18. Grill J, Kalifa C: High dose chemotherapy for childhood ependymoma (letter). J Neuro-Oncol 40: 97, 1998
19. Kedar A: Chemotherapy for pediatric brain tumors. Semin Pediatr Neurol 4: 320-332, 1997
20. Needle MN, Goldwein JW, Grass J, Cnaan A, Bergman I, Molloy P, Sutton L, Zhao H, Garvin Jr JH, Phillips PC: Adjuvant chemotherapy for the treatment of intracranial ependymoma of childhood. Cancer 80: 341-347, 1997
21. Siffert J, Allen JC: Chemotherapy in recurrent ependymoma. Pediatr Neurosurg 28: 314-319, 1998
22. Souweidane MM, Bouffet E, Finlay J: The role of chemotherapy in newly diagnosed ependymoma in childhood. Pediatr Neurosurg 28: 273-278, 1998
23. Feun U, Savaraj N, Landy HJ: Drug resistance in brain tumors. J Neurooncol 20: 165-176, 1994
24. Lehnert M: Multidrug resistance of human cancer. J Neuro-Oncol 22: 239-243, 1994
25. Phillips PC: Antineoplastic drug resistance in brain tumors. Neurol Clin 9: 383-404, 1991
26. Hishikawa Y, Abe S, Kinugasa S, Yoshimura H, Monden N, Isarashi M, Tachibana M, Nagasue N: Overexpression of metallothionein correlates with chemoresistance to cisplatin and prognosis in esophageal cancer. Oncology 54: 342-347, 1997
27. Jasani B, Schmid KW: Significance of metallothionein overexpression in human tumours. Histopathology 31: 211-214, 1997
28. Monden N, Abe S, Hishikawa Y, Kinugasa S, Nagasue N: Prognostic significance of the expressions of metallothionein, glutathion S-transpherase pi and P-glycoprotein in curatively resected gastric cancer. Oncology 54: 391-399, 1997
29. Shmid KW, Ellis IO, Gee M, Darke BM, Lees WE, Kay J, Gryer A, Stark JM, Hittmer A, Ofner D: Presence and possible significance of immunocytochemically demonstrable metallothionein overexpression in primary invasive ductal carcinoma of the breast. Virchows Arch (A) Pathol Anat 422: 153-159, 1993
30. Siu LL, Banerjee D, Imurana RJ, Pan X, Pflueger R, Tannock IF, Moore MJ: The prognostic role of p53, metallothionein, P-glycoprotein and MIB-1 in muscle invasive urothelial transitional cell carcinoma. Clin Cancer Res 4: 559-565, 1998
31. Uozaki H, Horiuchi H, Ishida T, Iijima T, Imamura T, Machinami R: Overexpression of resistance-related proteins (metallothioneins, glutathion S-transpherase pi, heat shock protein 27 and lung resistance-related protein) in osteosarcoma. Relationship with poor prognosis. Cancer 79: 2336-2349, 1997
32. Ali-Osman F, Bruner JM, Kultuk TM, Hess K: Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas. Clin Cancer Res 3: 2253-2261, 1997
33. Bossanyi von P, Diete S, Dietzmann K, Warich Kirches M, Kirches E: Immunohistochemical expression of P-glycoprotein and glutathione S-transferases in cerebral gliomas and response to chemotherapy. Acta Neuropathol (Berl) 94: 605-611, 1997
34. Korshunov A, Golanov A, Sycheva R, Pronin I, Fadeeva L: Prognostic value of the immunoexpression of chemoresistance-related proteins in cerebral glioblastomas. Neuropathology 19: 143-149, 1999
35. Chou PM, Barquin N, Gonzales Crussi F, Ridaura Sanz C, Tomita T, Reyes Mugica M: Ependymomas in children express the multidrug resistance gene: immunohistochemical and molecular biology study. Pediatr Pathol Lab Med 16: 551-561, 1996
36. Geddes JF, Vowle GH, Ashmore SM, Cockburn HA, Darling JL: Detection of multidrug resistance gene product (P-glycoprotein) expression in ependymomas. Neuropathol Appl Neurobiol 20: 118-121, 1994
37. Aschner M: The functional significance of brain metallothioneins. FASEB J 10: 1129-1136, 1996
38. Aschner M: Astrocyte metallothioneins (Mts) and their neuroprotective role. Ann NY Acad Sci 825: 334-347, 1997
39. Maier H, Jones C, Jasani B, Otner D, Zelger B, Schmid KW, Budka H: Methallothionein overexpression in human brain tumors. Acta Neuropathol (Berl) 94: 599-604, 1997
40. Sevlever G, Sinay V, Schultz M, Taratuto AL: Chemoresistance markers in the CNS tumors: their relationship with histological grading and proliferative activity (Abstract). Neuropathol Appl Neurobiol 22(suppl 1): 60, 1996
41. Kantor RR, Glardina SL, Bartolazzi A, Townsend AJ, Myers CE, Cowan KH, Longo DL, Natali PG: Monoclonal antibodies to glutathione S-transferase pi-immunohistochemical analysis of human tissues and cancers. Int J Cancer 47:193-201, 1991
42. Beiswanger CM, Diegmann MH, Novak RF, Philbert MA, Garessle TL, Reuhl KR, Lowndes HE: Developmental changes in the cellular distribution of glutathione and glutathione S-transferases in murine nervous system. Neurotoxicology 16: 425-440, 1995
43. Philbert MA, Bieswanger CM, Manson MM, Green JA, Novak RF, Primiano T, Reuhl KR, Lowndes HE: Glutathione S-transferases and gamma-glutamyl transpeptidase in the rat nervous system: a basis for differential susceptibility to neurotoxicants. Neurotoxicology 16:339-342, 1995
44. Hara A, Yamada H, Sakai N, Hirayama H, Tanaka T, Mori H: Immunocytochemical demonstration of the palcental form of glutathione S-transferase, a detoxifying enzyme in human gliomas. Cancer 66: 2563-2568, 1990
45. Grant R, Ironside JW: Glutathione S-transferases and cytochrome P450 detoxifying enzyme distribution in human cerebral glioma. J Neuro-Oncol 25:1-7, 1995
46. Huai Yun H, Secrest DT, Mark KS, Carney D, Brandquist C, Elmquist WF, Miller DW: Expression of multidrug resistance-associated proteins (MRP) in brain microvessel endothelial cells. Biochem Biophys Res Commun 243: 816-820, 1998
47. Becker I, Becker KF, Meyerman R, Hillt V: Multidrug-resistance gene MDR 1 is expressed in human glial tumors. Acta Neuropathol (Berl) 82: 516-519, 1991
48. Billson AL, Palmer JV, Walker DA, Lowe J: Multidrug-resistance gene (MDR 1) expression in neuro-axial tumours of children and young adults. Br J Neurosurg 8: 585-591, 1994
49. Dietzmann K, von Bossanyi P, Franke DS: Expression of P-glycoprotein as a multidrug resistance gene product in human reactive astrocytes and astrocytoma (in German). Zentralbl Pathol 140: 149-153, 1994
50. Henson JW, Cordon-Cardo C, Posner JB: P-glycoprotein expression in brain tumors. J Neurooncol 14: 37-43, 1992
51. Nabors MW, Griffin CA, Zehnbauer BA, Hruban RH, Phillips PC, Grossman SA, Brem H, Colvin OM: Multidrug resistance gene (MDR 1) expression in human brain tumors. J Neurosurg 75: 941-946, 1991
52. Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS: Overexpression of the methallothionein confers resistance to anticancer drugs. Science 241: 1813-1815, 1988
53. Doz F, Roosen N, Rosenblum ML: Metallothionein and anticancer agents: the role of metallothionein in cancer chemotherapy. J Neuro-Oncol 17: 123-129, 1993
54. Charles SM, Kenneth HC: Glutathione S-transferases and drug resistance. Cancer Cells 2: 15-22, 1990
55. Kartner N, Riordan JR, Ling V: Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221: 1285-1288, 1983